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Abstract
Successful prediction of the likely paths of tumor progression is valuable for diagnostic,
prognostic, and treatment purposes. Cancer progression models (CPMs) use cross-sec-
tional samples to identify restrictions in the order of accumulation of driver mutations and
thus CPMs encode the paths of tumor progression. Here we analyze the performance of
four CPMs to examine whether they can be used to predict the true distribution of paths of
tumor progression and to estimate evolutionary unpredictability. Employing simulations we
show that if fitness landscapes are single peaked (have a single fitness maximum) there is
good agreement between true and predicted distributions of paths of tumor progression
when sample sizes are large, but performance is poor with the currently common much
smaller sample sizes. Under multi-peaked fitness landscapes (i.e., those with multiple fit-
ness maxima), performance is poor and improves only slightly with sample size. In all
cases, detection regime (when tumors are sampled) is a key determinant of performance.
Estimates of evolutionary unpredictability from the best performing CPM, among the four
examined, tend to overestimate the true unpredictability and the bias is affected by detection
regime; CPMs could be useful for estimating upper bounds to the true evolutionary unpre-
dictability. Analysis of twenty-two cancer data sets shows low evolutionary unpredictability
for several of the data sets. But most of the predictions of paths of tumor progression are
very unreliable, and unreliability increases with the number of features analyzed. Our results
indicate that CPMs could be valuable tools for predicting cancer progression but that, cur-
rently, obtaining useful predictions of paths of tumor progression from CPMs is dubious, and
emphasize the need for methodological work that can account for the probably multi-peaked
fitness landscapes in cancer.
Author summary
Knowing the likely paths of tumor progression is instrumental for cancer precision medi-
cine as it would allow us to identify genetic targets that block disease progression and to
improve therapeutic decisions. Direct information about paths of tumor progression is
scarce, but cancer progression models (CPMs), which use as input cross-sectional data on
genetic alterations, can be used to predict these paths. CPMs, however, make assumptions
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about fitness landscapes (genotype-fitness maps) that might not be met in cancer. We
examine if four CPMs can be used to predict successfully the distribution of tumor pro-
gression paths; we find that some CPMs work well when sample sizes are large and fitness
landscapes have a single fitness maximum, but in fitness landscapes with multiple fitness
maxima prediction is poor. However, the best performing CPM in our study could be
used to estimate evolutionary unpredictability. When we apply the best performing CPM
in our study to twenty-two cancer data sets we find that predictions are generally unreli-
able but that some cancer data sets show low unpredictability. Our results highlight that
CPMs could be valuable tools for predicting disease progression, but emphasize the need
for methodological work to account for multi-peaked fitness landscapes.
Introduction
Improving our ability to predict the paths of tumor progression is helpful for diagnostic, prog-
nostic, and treatment purposes as, for example, it would allow us to identify genes that block
the most common paths of disease progression [1–4]. This interest in predicting paths of pro-
gression is not exclusive to cancer (see reviews in [5, 6]). For example, in some cases antibiotic
resistance shows parallel evolution with mutations being acquired in a similar order [7], and
here “Even a modest predictive power might improve therapeutic outcomes by informing the
selection of drugs, the preference between monotherapy or combination therapy and the tem-
poral dosing regimen (. . .)” [8, p. 243i]. But detailed information about the paths of tumor
evolution and their distribution, obtained from multiple within-patient samples with timing
information, is not available.
Cancer progression models (CPMs), such as conjunctive Bayesian networks (CBN) [9–11],
oncogenetic trees (OT) [12, 13], CAncer PRogression Inference (CAPRI) [14, 15], or CAncer
PRogression Extraction with Single Edges (CAPRESE) [16], can be used to predict paths of
tumor progression. CPMs were originally developed to identify restrictions in the order of
accumulation of mutations during tumor progression from cross-sectional data [17, 18]. But
CPMs also encode all the possible mutational paths or trajectories of tumor progression, from
the initial genotype to the genotype with all driver genes mutated (see Fig 1); in fact, muta-
tional pathways and evolutionary trajectories are already mentioned in the papers that describe
CBN [10], CAPRI [14, 15] and in general overviews of CPMs [18]. Thus, CPMs could improve
our ability to predict disease progression by leveraging on the available, and growing, number
of cross-sectional data sets.
The first question we address in this study is whether we can predict the paths of tumor pro-
gression using CPMs. To answer this question we will examine how close to the truth are the
predictions made by four CPMs (CBN, OT, CAPRI, and CAPRESE) about the distribution of
paths of tumor progression. We have adapted the output from the CPMs (the restrictions in
the order of accumulation of mutations) to predict mutational pathways, and assessed the
quality of these predictions. When addressing this question we need to take into account possi-
ble deviations from the models assumed by CPMs. In particular, most CPMs assume that the
acquisition of a mutation in a driver gene, when all its possible dependencies on other genes
are satisfied, does not decrease the probability of gaining a mutation in another driver gene
[19]. In other words, acquiring driver mutations (when their dependencies on other genes are
satisfied) cannot decrease fitness. This implies that the fitness landscapes assumed by CPMs,
with respect to the driver genes, only have a single fitness maximum, the genotype with all
drivers mutated (see Fig 1; note that there can be multiple fitness maxima if we include genes
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that are unconditionally deleterious —see section 4 of S2 Text). But it is likely that many cancer
fitness landscapes have several local fitness maxima (i.e., they are rugged, multi-peaked land-
scapes): this can happen if there are many combinations of a small number of drivers, out of a
larger pool of drivers [20], that result in the escape genotypes; moreover, synthetic lethality is
Fig 1. Fitness landscapes, paths of tumor progression, and directed acyclic graphs (DAGs) of restrictions in the order of accumulation of
mutations for the three types of landscapes used. (A) Representable; (B) Local maxima; (C) Rough Mount Fuji (RMF). Top row: partial fitness
landscapes (representation based on [23], but only accessible genotypes are shown); genotypes are shown as sequences of 0s and 1s, where “1010”
means a genotype with the first and third driver genes mutated; the vertical position of a genotype is its fitness; its horizontal position on the x-axis is
given by its Hamming distance to the “0000” genotype. Green segments connect mutational neighbors of increasing fitness. The inset in the first row
shows the DAG of restrictions in the order of accumulation of mutations that applies to (A) and (B). A DAG of restrictions shows genes (not genotypes)
in the nodes; an arrow from gene i to gene j means that a mutation in i must occur before a mutation in j can occur; an arrow indicates a direct
dependency of a mutation in gene j on a mutation in gene i. In the figure, a mutation in the fourth gene can be observed only if both the second and
third genes are mutated. Note that among the models considered in this paper, CAPRESE and OT can only represent trees (so they can not account for
the fourth gene having two, or more, incoming arrows). The absence of an arrow between two genes means that there are no direct dependencies
between the two genes. Bottom row: fitness graphs or graphs of mutational paths; in fitness graphs nodes are genotypes and arrows point toward
mutational neighbors of higher fitness (i.e., two genotypes connected by an arrow differ in one mutation that increases fitness [24–26]). These fitness
graphs show all the paths of tumor progression, the set of accessible mutational paths and adaptive walks that, under the restriction that there can be no
back mutations, start from the “0000” genotype and end in a fitness maximum. When evolution runs until fixation in a fitness maximum, each path
from “0000” to a fitness maximum corresponds to a different Line of Descent (LOD). For (B) and (C), gray edges and nodes in the fitness graphs show
edges and nodes that are present in (A) but missing in (B) or (C). Under CPMs, since each new driver mutation with its dependencies satisfied increases
fitness, all accessible genotypes that differ by exactly one mutation are connected in the fitness graph, as shown in (A), and the genotype with all driver
genes mutated is the single fitness maximum (see also section 4 of S2 Text for local maxima from unconditionally deleterious mutations). For (B), the
fitness landscape —and its fitness graph— has the same accessible genotypes as the fitness landscape in (A). But the fitness landscape in (B) has three
maxima and, compared to (A), there are fewer paths to the genotype with all genes mutated, “1111”, and several paths end in the other two maxima
(“1100”, “1010”). Thus, the fitness graph of (B) does not fulfill the assumptions of CPMs. Compared to the fitness graph of (A), in the fitness graph of
(B) not all accessible genotypes that differ by one mutation are connected —e.g., genotypes “1100” and “1110”. In terms of acquisition of mutations, in
(B), and in contrast to (A), we cannot reach genotype “1110” from genotype “1100”, even when a mutation in the third gene does not depend on any
previous mutation according to the DAG of restrictions. So if we go from “1000” to “1100”, the acquisition of the second mutation precludes acquiring
the third mutation (a violation of an assumption of CPMs), and this creates a local fitness maximum. The fitness landscape in (C) cannot be represented
by any DAG of restrictions: no DAG of restrictions can account at the same time for the presence of genotypes “1000”, “0100”, “0010”, and the absence
of every double mutant with the first gene mutated. Relative to (A), the fitness graph in (C) is missing both paths and genotypes (relative to the fitness
graph from any possible DAG of restrictions it could either be missing and/or adding genotypes and paths).
https://doi.org/10.1371/journal.pcbi.1007246.g001
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common in both cancer cells [21, 22] and the human genome [27], and it can lead to local fit-
ness maxima when it affects mutations that individually increase fitness—see also [28]. Thus,
to examine if CPMs can be used to predict paths of tumor progression we will need to assess
how the quality of the predictions is affected by multi-peaked fitness landscapes.
The second question addressed in this paper is whether we can use CPMs to estimate evolu-
tionary unpredictability, regardless of the performance when predicting the actual paths of
tumor progression. A model could be useful if it suggests few paths are possible, even if its
actual predictions about the distribution of paths are not trustworthy. Conversely, predicting
correctly the distribution of paths of tumor progression might be of little importance in sce-
narios where the true evolutionary unpredictability itself is very large (where disease progres-
sion follows a very large number of possible paths); for practical purposes, forecasting here
would be useless.
To address the above questions (can we predict the paths of tumor progression using
CPMs?; can we estimate evolutionary unpredictability using CPMs?) we use evolutionary
simulations on 1260 fitness landscapes that include from none to severe deviations from the
assumptions that CPMs make about the structure of fitness landscapes, and we analyze the
data with four different CPMs, whose predictions about restrictions in the order of accumula-
tion of mutations we have adapted to provide probabilities of paths of tumor progression. This
paper does not attempt to understand the determinants of evolutionary (un)predictability (see,
e.g., [5, 6, 25, 29, 30]) but, instead, we focus on the effects of evolutionary unpredictability for
CPMs. This is why we use variation in key determinants of evolutionary unpredictability (e.g.,
variation in population sizes and mutation rates) but these factors are only used to generate
variability in unpredictability, and not themselves the focus of the study. To better assess the
quality of predictions, we use sample sizes that cover the range from what is commonly used to
what are much larger sample sizes than currently available. We also include variation in the
cancer detection process or detection regime (when cancer samples are taken, or when patients
are sampled), since previous studies have shown that it affects the quality of inferences from
CPMs [31].
We have shown before [31] that the performance of two CPMs (CBN and CAPRI) for pre-
dicting accessible genotypes degrades considerably when the fitness landscapes contain recip-
rocal sign epistasis. That study focused on predicting accessible genotypes and its results
cannot provide an answer to the questions about predicting paths of tumor progression and
estimating evolutionary unpredictability. We are extending our previous study to answer
whether CPMs can be used to predict paths of progression and to estimate evolutionary unpre-
dictability. To address these questions we need to look directly at the prediction of paths (not
genotypes), and compare them with the true paths of progression, as we do in the current
work. Thus, the two studies differ in objectives, methods (here we use a larger number of
CPMs, we follow evolution until fixation, and we develop procedures to compare predicted
with true paths of tumor progression), and scenarios considered (the types fitness landscapes
used and the extent of evolutionary unpredictability); see details in S1 Text.
Here we find that the agreement between the predicted and true distributions of paths
is generally poor, unless sample sizes are very large and fitness landscapes conform to the
assumptions of CPMs. Both detection regime and evolutionary unpredictability itself have
major effects on performance. But in spite of the unreliability of the predictions of paths of
tumor progression, we find that CPMs can be useful for estimating upper bounds to the true
evolutionary unpredictability.
What are the implications of our results for the analysis and interpretation of the use of
CPMs with cancer data sets? We analyze twenty-two real cancer data sets with H-CBN, the
best performing CPM in the simulations. We cannot examine how close predictions are to the
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truth, since the truth is unknown; thus, we use bootstrap samples to examine the reliability of
the inferences. Many of the cancer data sets reflect conditions where useful predictions could
be possible, based on the estimates of evolutionary unpredictability from H-CBN. But for most
data sets these results are thwarted by the unreliability of the predictions themselves, which
increases with the number of features analyzed. Our results question uncritical use of CPMs
for predicting paths of tumor progression, and suggest the need for methodological work that
can account for the probably multi-peaked fitness landscapes in cancer.
Materials and methods
This paper involves both a simulation study where results from four CPMs (CBN —variants
H-CBN and MCCBN—, OT, CAPRI —variants CAPRI_AIC and CAPRI_BIC—, and CAPR-
ESE) are compared to the known truth from the simulations, and the analysis of twenty-two
cancer data sets using the best performing of the above CPMs (H-CBN). Section Cancer Pro-
gression Models used and paths of tumor progression describes the CPMs used and how
predicted paths of tumor progression are obtained from them. Section Overview of the
simulation study provides an overview of the simulation study. Sections Fitness landscapes to
Detection regimes and obtaining data sets from the simulations provide details on how the
simulations were conducted. How the performance of CPMs was assessed is explained in sec-
tion Measures of performance and predictability. Section Characteristics of the simulated fit-
ness landscapes and genotypes summarizes the main features of the simulated landscapes and
data sets used to evaluate the performance of the CPMs. The cancer data sets and the methods
used to analyze them are described in section Cancer data sets.
Cancer progression models used and paths of tumor progression
We have compared four distinct CPMs: CBN, OT, CAPRI, and CAPRESE. Two of the models
used, CBN and CAPRI, have been used in two variants (H-CBN and MCCBN for CBN,
CAPRI_AIC and CAPRI_BIC for CAPRI), yielding a total of six different procedures for
obtaining CPMs. Only a brief overview of these CPMs is provided here; detailed descriptions
can be found in the original references for each model: H-CBN [9, 10], MCCBN [11], OT [12,
13], CAPRI [14, 15], and CAPRESE [16]. (Other CPMs that we are aware of include DiP [32],
bcbn [33] and RESIC [34, 35]; we do not consider these methods here because they are too
slow for routine work, have no software available, or have dependencies on non-open source
external libraries —see S4 Text).
The CPMs considered try to identify restrictions in the order of accumulation of muta-
tions from cross-sectional data. CPMs assume that the different observations in the cross-
sectional data set constitute independent realizations of evolutionary processes where the
same constraints hold for all tumors [10, 17, 18]. Thus, a data set can be regarded as a set of
replicate evolutionary experiments where all individuals are under the same genetic con-
straints. For the four CPMs considered in this paper, the cross-sectional data is a matrix of
subjects (or individuals) by driver alteration events, where each entry in the matrix is binary
coded as mutated or not-mutated (or, equivalently, altered or non-altered). CPMs assume
there are no back mutations in these events —i.e., once gained, an alteration is not lost.
CPMs further assume that the driver genes are known. For the simulations, we will refer to
these driver alteration events as “genes”, but they can be individual genes, parts or states of
genes, or modules or pathways made from several genes (e.g., [10, 15]). When we analyze the
twenty-two cancer data sets (see section Cancer data sets) we will use the generic term “fea-
tures” as some of those data sets use genes whereas others use pathway or module informa-
tion. CPMs assume that all tumors start cancer progression without any of the mutations
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considered in the study (the above matrix of subjects by driver alterations), but other muta-
tions could be present that have caused the initial tumor growth. All these other mutations
are absorbed in the root node from which cancer is initiated [35]; note that the way the data
are simulated to generate cross-sectional observations (see section Overview of the simula-
tion study) is consistent with this assumption.
The above assumptions are common to the CPMs considered. The models examined here
differ, however, in the types of restrictions they can represent and on their model fitting proce-
dures. Both OT [12, 13] and CAPRESE [16] describe the accumulation of mutations with
order constraints that can be represented as trees. Thus, among the “representable” fitness
landscapes used in this paper (section Evolutionary simulations), OT and CAPRESE can only
faithfully model the subset that are trees, those where a gene mutation has a direct dependency
on only one other gene’s mutation. A key difference between OT and CAPRESE is that CAPR-
ESE reconstructs these models using a probability raising notion of causation in the frame-
work of Suppes’ probabilistic causation, whereas in OT weights along edges can be directly
interpreted as probabilities of transition along the edges by the time of observation [12, p. 4].
In contrast to OT and CAPRESE, both CAPRI [14, 15] and CBN [9–11] allow modeling the
dependence of an event on more than one previous event: the output of the models are
directed acyclic graphs (DAGs) where some nodes have multiple parents, instead of a single
parent (as in trees). CAPRI tries to identify events (alterations) that constitute “selective advan-
tage relationships”, again using probability raising in the framework of Suppes’ probabilistic
causation. We have used two versions of CAPRI, that we will call CAPRI_AIC and CAPRI_
BIC, that differ in the penalization used in the maximum likelihood fit, Akaike Information
Criterion (AIC), or Bayesian Information Criterion (BIC), respectively. For CBN we have also
used two variants, H-CBN, described in [9, 10] that uses simulated annealing with a nested
expectation-maximization (EM) algorithm for estimation, and MCCBN, described in [11],
that uses a Monte-Carlo EM algorithm. Thus, these six procedures can be divided into three
groups: models that return trees (OT and CAPRESE) and two families of models that return
DAGs, CBN (H-CBN and MCCBN) and CAPRI (CAPRI_AIC and CAPRI_BIC).
Because (the transitive reduction of) a DAG of restrictions determines a fitness graph
(see Fig 1 and [31]), the set of paths to the maximum encoded by the output from a CPM is
obtained from the fitness graph. This we did for all models. From H-CBN and MCCBN we
can also obtain the estimated probability of each path of tumor progression to the fitness maxi-
mum, since both H-CBN and MCCBN return the parameters of the waiting time to occur-
rence of each mutation (given its restrictions are satisfied; e.g., [11, p. i729], [9, section 2.2],
or [36]; details and example in section 3 of S4 Text). It is also possible to perform a similar
operation with the output of OT, and use the edge weights from the fits of OT to obtain the
probabilities of transition to each descendant genotype and, from them, the probabilities of the
different paths to the single fitness maximum. It must be noted that these probabilities are not
really returned by the model, since the OTs used are untimed oncogenetic trees [12, 13]. We
will refer to paths with probabilities assigned in the above way as probability-weighted paths.
For CAPRESE and CAPRI, it is not possible to map the output to different probabilities of
paths of progression (see section 3 of S4 Text) and in all computations that required probabil-
ity of paths we assigned the same probability to each path.
Overview of the simulation study
We have used simulations of tumor evolution on fitness landscapes of three different types
(see Fig 1), for landscapes of 7 and 10 genes, under different initial population sizes and muta-
tion rates. We have used a total of 1260 fitness landscapes = 2 conditions of numbers of genes
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x 3 types of fitness landscapes x 3 initial population sizes x 2 mutation regimes x 35 random fit-
ness landscapes for each combination of conditions. For each one of the 1260 fitness land-
scapes, we simulated 20000 independent evolutionary processes (with the specified parameters
for initial population size and mutation rate) using a logistic-like growth model; each simu-
lated evolutionary process was run until one of the genotypes at the local fitness maxima (or
the single fitness maximum) reached fixation. Each set of 20000 simulated evolutionary pro-
cesses was then sampled under three detection regimes, so that each fitness landscape gener-
ated three sets of 20000 simulated genotypes. From each of these sets, we obtained five
different splits of the genotypes for each of three sample sizes (50, 200, 4000); thus a total of
56700 (= 1260 x 3 x 3 x 5 combinations of 1260 fitness landscapes, 3 detection regimes, 3 sam-
ple sizes, 5 splits) data sets were produced. Each of these 56700 data sets was analyzed with
every one of the CPMs compared (H-CBN, MCCBN, OT, CAPRI_AIC, CAPRI_BIC, and
CAPRESE), to obtain predicted paths of tumor progression. These predictions were then com-
pared with the true, recorded, paths of tumor progression from the simulations (see section
Measures of performance and predictability). A schematic view of the simulation study is pro-
vided in Fig 2.
Fitness landscapes
We have used three different kinds of random fitness landscapes (see Fig 1). Representable
fitness landscapes are fitness landscapes for which a DAG of restrictions exists with the same
accessible genotypes and accessible mutational paths. (Accessible mutational path: a trajectory
through a collection of genotypes, where each genotype is separated from the preceding geno-
type by one mutation, along which fitness increases monotonically [26]; accessible genotypes:
genotypes along accessible mutational paths). An example of a representable fitness landscape
with its corresponding DAG of restrictions and fitness graph is shown in Fig 1A. A defining
characteristic of representable fitness landscapes is that all accessible genotypes that differ by
exactly one mutation are connected in the fitness graph; thus, with respect to the driver genes,
there is a single fitness maximum, the genotype with all driver genes mutated, and all accessible
mutational paths in the fitness graph end in that single maximum. For representable fitness
landscapes there is a one-to-one correspondence between DAGs of restrictions and fitness
graphs.
In local maxima fitness landscapes (Fig 1B) the set of accessible genotypes can be repre-
sented by a DAG of restrictions, but there are local fitness maxima and the fitness graph has
missing paths; the genotype with all genes mutated might or might not be the genotype with
largest fitness. In other words, in the local maxima fitness landscapes, the DAG of restrictions
and the fitness landscape agree on which genotypes should be accessible and which genotypes
should not be accessible; what the local maxima landscapes are missing are mutational paths to
the genotype with all genes mutated, because we have introduced local fitness maxima. Once
we introduce local maxima there is no longer a one-to-one correspondence between DAGs of
restrictions and fitness graphs (thus, there is no longer a one-to-one correspondence between
DAGs of restrictions and sets of tumor progression paths). These local maxima landscapes
should not be as challenging to CPMs as the DAG-derived non-representable fitness land-
scapes used in [31], as those also missed some genotypes that should exist under the DAG of
restrictions. This is by design: here we want to isolate the effect of multi-peaked landscapes or
local maxima (or, equivalently, missing paths), without the additional burden, for the CPMs,
of missing genotypes.
The third type of fitness landscapes used are Rough Mount Fuji (RMF) fitness landscapes.
The RMF model [25, 37] combines a random House of Cards model (where fitness is assigned
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Fig 2. Scheme of the simulation study. (A) On each of the 1260 fitness landscapes, (B) 20000 evolutionary processes were simulated. The set of 20000
evolutionary processes from a fitness landscape were then (C) sampled under three detection regimes, obtaining one observation per simulation under
each detection regime, (D) leading to 20000 observations that are enriched in large-sized tumors —large detection regime—, 20000 observations
enriched on small-sized tumors —small detection regime—, and 20000 observations with uniform distribution with respect to the logarithm of tumor
size (so that the large and small detection regimes emulates cases when cancer tends to be detected at late or early stages, respectively —see text). (E)
From each of the individual observations, we obtained the genotype of the most common clone; therefore, (F) each fitness landscape provides 3 sets of
20000 genotypes, one for each detection regime. (G) These sets were split in 5 non-overlapping sets of 50 observations, 5 non-overlapping sets of 200
observations, and 5 non-overlapping sets of 4000 observations. Each of these data sets was analyzed with each of the CPMs considered to obtain the
predicted paths of tumor progression.
https://doi.org/10.1371/journal.pcbi.1007246.g002
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to genotypes by independently sampling from a fixed probability distribution) and an additive
fitness landscape (where the reference genotype, or the genotype with largest fitness, need not
be the one with all genes mutated). The RMF model is a very flexible one, where the rugged-
ness of the landscape can be modified by changing the ratio of the additive component (the
change in fitness per unit increase in Hamming distance from the reference genotype) relative
to the variance of the random fitness component (the House of Cards component). The RMF
model has been useful to model empirical fitness landscapes [25, 26, 37]. RMF fitness land-
scapes generally have multiple local fitness maxima and considerable reciprocal sign epistasis
and thus not even the set of accessible genotypes can be represented by a DAG of restrictions
(see [31], and Fig 1).
We generated the DAG-derived representable fitness landscapes by generating a random
DAG of restrictions and from it the fitness graph. We then assigned birth rates to genotypes
using an iterative procedure on the fitness graph where, starting from the genotype without
any driver mutation with a birth rate of 1, the birth rate of each descendant genotype was set
equal to the maximum fitness of its parent genotypes times a random uniform variate between
1.01 and 1.19 (U(1.01, 1.19)) yielding, therefore, an average multiplicative increase in fitness of
0.1 (which is within values previously used: [4, 38, 39]). The birth rate of genotypes that were
not accessible according to the DAG of restrictions was set to 0. For example, if the DAG of
restrictions was the one shown in Fig 1A, a cell with genotype “1001” would have a birth rate
of 0, since the dependencies of the DAG of restrictions are not satisfied —mutations in genes 2
and 3 must occur before a mutation in gene 4. Therefore, this simulation scheme strictly
adheres to the assumptions about accessible and non-accessible genotypes under the CPM
model. (For the growth model used here —see below— birth rates determine fitness at any
population size as death rates are identical for all genotypes and depend only on population
size. Genotypes with a birth rate of 0 are never added to the population and, thus, they cannot
mutate before dying). We generated the DAG-derived local maxima fitness landscapes by first
generating a random DAG and from it the fitness graph, identically to what was done for rep-
resentable fitness landscapes. Though in contrast to representable fitness landscapes, before
assigning fitness to genotypes a random selection of edges of the fitness graph were removed
so that all accessible genotypes remained accessible but now from a possibly much smaller set
of parents. Birth rate was then assigned as for the representable fitness landscapes (using the
iterative procedure on the fitness graph, where birth rate of descendant genotype = max(birth
rate parent genotypes) � U(1.01, 1.19), and with all non-accessible genotypes with a birth rate
of 0). For each DAG we repeated this procedure 50 times, and kept the one that introduced
the largest number of local maxima. Creating local maxima almost always resulted in creating
reciprocal sign epistasis (see also section Characteristics of the simulated fitness landscapes
and genotypes and S2 Text). We generated the RMF fitness landscapes by randomly choosing
the reference genotype (i.e., the genotype with the largest fitness) and the decrease in birth rate
of a genotype per each unit increase in Hamming distance from the reference genotype (which
affects the ruggedness of the landscape); see details in S2 Text.
Evolutionary simulations
Once a fitness landscape had been generated, we simulated 20000 evolutionary processes
(step B in Fig 2). We used the continuous-time, logistic-like model of [38], in which death
rate depends on total population size, as implemented in OncoSimulR [40], with the specified
parameters of initial population size and mutation rate (below). Each individual evolutionary
process was run until one of the genotypes at the local fitness maxima (or the single fitness
maximum) reached fixation (see details in S3 Text). We also verified that all 7 or 10 genes had
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appeared in at least some genotypes, i.e., were part of the paths of tumor progression. If this
condition was not fulfilled, a new fitness landscape was generated and the processes started
again. This procedure is independent of the detection process that returns the genotypes ana-
lyzed by the CPMs (section Detection regimes and obtaining data sets from the simulations).
We used three initial population sizes, 2000, 50000, and 1 × 106 cells, for the simulations;
these cover a range of population sizes at tumor initiation that have previously been used in
the literature (e.g., [10, 38, 41, 42]). We also used two mutation regimes; in the first one, all
genes had a common mutation rate of 1 × 10−5; in the second, genes had different mutation
rates, uniformly distributed in the log scale between (1/5) 1 × 10−5 and 5 × 10−5 (i.e., the largest
ratio between largest and smallest mutation rates was 25), so that the arithmetic mean of muta-
tion rates was 1.5 × 10−5 and the geometric mean 1 × 10−5. These mutation rates are within
ranges previously used in the literature [38, 39, 43], with a bias towards larger numbers (since
we use only 7 or 10 genes relevant for population growth and we could be modeling pathways,
not individual genes). Initial population size and mutation rates are not of intrinsic interest
here (since our focus are not the determinants of evolutionary predictability per se), but are
used to generate variability in evolutionary predictability and to allow for deviations from the
strong-selection-weak-mutation (SSWM) regime [25]; see section Characteristics of the simu-
lated fitness landscapes and genotypes.
Only in the representable fitness landscapes are simulations restricted to move uphill in the
fitness landscapes. In all three types of fitness landscapes, mutations can lead to either increases
or decreases in fitness. In the representable and local maxima fitness landscapes, as explained
above, mutation events that do not fulfill the restrictions in the order of accumulation of muta-
tions lead to a birth rate (and, thus, fitness) of 0. Therefore, in the simulations in representable
and local maxima fitness landscapes, no path from the “0000” genotype to a fitness maximum
can ever go through a non-accessible genotype. This is by design, so that these fitness land-
scapes strictly adhere to the assumption of CPMs about restrictions in the accumulation of
mutations. But in both RMF and local maxima fitness landscapes it is possible to move through
a fitness valley (i.e., make moves from ancestor to descendant that are not always monotoni-
cally increasing in fitness), phenomena that are more frequent as we deviate from the SSWM
assumption ([25]; commented example in section 5 of S3 Text). (Note that this is possible in
local maxima fitness landscapes, even when non-accessible genotypes can never be part of evo-
lutionary paths, because with no back mutations an accessible genotype can be along an uphill
path when coming from one ancestor but in a valley when coming from another ancestor; no
such genotypes can exist in the representable fitness landscape as in the representable land-
scapes all accessible genotypes that differ by exactly one mutation are connected in the fitness
graph). In addition, in the RMF fitness landscape, we can move through fitness valleys of non-
accessible genotypes as non-accessible genotypes need not have a birth rate of 0 in the RMF;
see section 5 of S3 Text).
Detection regimes and obtaining data sets from the simulations
To obtain the genotypes that were analyzed by the CPMs, we first sampled the simulated evo-
lutionary processes, obtaining one observation per evolutionary processes, using three differ-
ent detection regimes (Fig 2C and 2D); then, for each observation of each detection regime,
we obtained the genotype corresponding to each observation (Fig 2E), which lead to matrices
of 20000 genotypes (Fig 2F); finally we split these matrices into non-overlapping subsets to be
analyzed with the CPMs (Fig 2G).
The three detection regimes differ in the distribution of sizes of the sampled tumors (Fig
2D). Under the large detection regime a large fraction of the samples correspond to large
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tumors. In contrast, under the small detection regime a large fraction of the samples corre-
spond to small tumors. Finally, under the uniform detection regime the distribution of sizes of
the sampled tumors is approximately uniform. Thus, the large detection regime would emulate
scenarios where cancer tends to be detected at late, advanced stages, and the small detection
regime would emulate scenarios where cancer tends to be detected at early stages.
To implement these detection regimes, we drew random deviates from beta distributions
with parameters B(1, 1), B(5, 3), and B(3, 5) (for uniform, large, and small, respectively),
rescaled them to the range of the log-transformed distribution of observed tumor sizes (log of
number of cells), and obtained the observation with population size closest to the target (see
details in section 2 in S3 Text). (We used the log-scale of tumor size because in the model of
[38] tumor population size increases logarithmically with number of driver mutations; thus,
distributions of sampled tumors that are biased towards large sizes in the log scale will mimic
sampling of late-stage tumors —tumors with a large number of drivers—, and distributions
of sampled tumors that are biased towards small sizes in the log scale will mimic sampling of
early-stage tumors, as intended).
For each observation, the genotype returned was the genotype of the most abundant clone
(Fig 2E). Finally, the set of 20000 genotypes (Fig 2F) was then split into five sets of non-over-
lapping data sets for each of the three sample sizes of 50, 200, and 4000 (Fig 2G). These are the
data sets that were analyzed with the CPMs.
Measures of performance and predictability
We have characterized evolutionary unpredictability using the diversity of Lines of Descent
(LODs). LODs were introduced by [30] and “(. . .) represent the lineages that arrive at the
most populated genotype at the final time” (p. 572). In other words, in our simulations a LOD
is a sequence of parent-child genotypes, from the initial genotype to a local maximum: a LOD
is the path that a tumor has taken until fixation. The final genotype in a LOD is a local fitness
maximum, but there are no guarantees that any intermediate genotype in the LOD will have
been the most common genotype at any time point (especially under deviations from SSWM
such as clonal interference and stochastic tunneling [25, 30, 44]). As in [30], we can use the
entropy of these paths to measure the indeterminism of the paths of evolution, or evolutionary
unpredictability, and we will define Sp = −∑pi ln pi, where pi is the observed probability of
each LOD (each path) computed from the 20000 simulations, and the sum is over all paths or
LODs. Evolutionary unpredictability, as estimated by the CPMs, will analogously be defined as
Sc = −∑qj ln qj, where qj is the probability of each path to the maximum according to the cancer
progression model considered, and the sum is over all paths predicted by the CPMs. ([36] nor-
malizes predictability by dividing by the maximum entropy, similar to dividing by the prior
entropy in the “information gain” statistic in [5]; but the maximum entropy is a constant for
each number of genes, i.e., 7! or 10! for our simulations).
To measure how well CPMs predict tumor progression, we used three different statistics.
To compare the overall similarity of the distribution of paths predicted by CPMs with the true
observed one (i.e., the distribution of LODs) we used the Jensen-Shannon divergence (JS) [45,
46], scaled between 0 and 1 (equivalent to using the logarithm of base 2). JS is a symmetrized
Kullback-Leibler divergence between two distributions and is defined even if the two distribu-
tions do not have the same sample space, i.e., even if P(i) 6¼ 0 and Q(i) = 0 (or Q(i) 6¼ 0 and
P(i) = 0), as can often be the case for our data. A JS value of 0 means that the distributions are
identical, and a value of 1 that they do not overlap. Therefore, predictions of CPMs are closer
to the truth the smaller the value of JS. The sum of the probabilities of the paths in the LODs
that are not among the paths allowed by the CPMs, P(¬DAG|LOD), is equivalent to 1—recall.
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Larger values of 1-recall mean that the CPM is not capturing a large fraction of the evolution-
ary paths to the maximum (or maxima). The sum of the predicted probabilities of paths
according to the CPMs that are not used by evolution (i.e., that are not LODs), P(¬LOD|DAG),
is equivalent to 1—precision. Larger values of 1-precision mean that the CPMs predict larger
numbers of paths to the maximum that are not used by evolution. In S6 Text we also use as sta-
tistic the probability of recovering the most common LOD; we will rarely refer to this statis-
tic in the main paper since it follows a pattern very similar to recall (section 2 in S6 Text).
Statistics 1-recall and 1-precision can overestimate performance: they could both have a value
of 0, even when JS is very close to 1 (see example in section 4 in S4 Text). Thus, the main over-
all performance measure will be JS.
Comparing paths from CPMs with LODs of different lengths. When all paths from the
CPM and the LOD have equal length (they end in a genotype with the same number of genes
mutated, K) computing the above statistics is straightforward. But paths could differ in length.
In fitness landscapes with local maxima, LODs can differ in length; some LODs could have a
length (or number of mutations of the fixated genotype), Ki, shorter than the length of the
paths from the CPM, KC (all paths from a CPM have the same number of mutations, since all
arrive at the genotype with all KC genes mutated). It is also possible that some or all Ki> KC,
i.e., some or all LODs have a length larger than the length of the paths from the CPM. This will
happen if the CPM has been built from a data set that contains fewer genes than the number
of genes in the landscape (e.g., because one or more genes were absent —see section 2 in S4
Text); if the sampled data set has fewer genes than the landscape in a representable fitness land-
scape, then all Ki> KC (as Ki will be equal to either 7 or 10).
To compute JS, 1-recall, and 1-precision that will cover all those cases we used the following
procedure (that reduces to the simpler procedure in the previous section when all Ki = KC). Let
i and j denote two paths, one from the LOD and the other from the CPM, with corresponding
probabilities pi and qj; in contrast to the previous section, and to minimize notation, i, j (and
pi, qj) could refer to a path from the LOD and a path from the CPM or, alternatively, a path
from the CPM and a path from a LOD. Let Ki, Kj denote the length of paths i and j, respec-
tively. At least one set of either Kis or Kjs has all elements identical (e.g., if j refers to indices
of the paths from the CPM, it is necessarily the case that K1 = K2 = . . . = Km = KC, with m the
total number of different paths from the CPM).
Now if Ki> Kj and the path i up to Kj mutations (i.e., from the “0000” genotype to the geno-
type with Kj mutations) is identical to j, then path j is included in path i: all of qj is accounted
for by i. This also means that path i is partially included in (or accounted for by) path j, but
a fraction of it, (Ki − Kj)/Ki, is missing or unaccounted for. The above applies directly to calcu-
lations of 1-recall and 1-precision. For computing JS, there will be two entries in the vectors
with the probability distributions that will be compared: P ¼ pi
Kj
Ki
; pi
Ki   Kj
Ki
� �
, Q = [qi, 0].
This procedure can be applied to all elements i, j, summing all unmatched entries:
P
pi
Ki   Kj
Ki
is the total flow in the set of paths i that cannot be matched by the js because they are shorter.
To simplify computations, that unmatched term can also include ∑pu, where u denotes those
paths i that do not match any j. Conversely, all paths i with Ki> Kj such that the paths become
indistinguishable up to Kj can be summed in a single entry so that we obtain
P
pi
Kj
Ki
and
P
pi
Ki   Kj
Ki
for the matched and unmatched fractions, respectively. All computations have their
corresponding counterparts for elements i, j when Ki< Kj. The above procedure is applied at
all distinct k, the number of mutations of the final genotypes of the true LODs. The final JS
(and 1-precision and 1-recall) is the weighted sum of each of those JS (and 1-precision and
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1-recall), weighted by wk, the frequency of all paths from the LOD that end at k mutations.
This procedure results in unique JS (remember the K are all the same for at least one of the sets
of paths) as well as unique 1-precision and 1-recall, and it reduces to the procedure (see above)
when all Ki are equal and equal to all Kj. A commented example and further details are pro-
vided in the Supporting Information (section 5.1 in S4 Text).
Statistical modeling of performance. We have used generalized linear mixed-effects
models, with a beta model for the dependent variable [47–49], to model how JS, 1-recall, and
1-precision, are affected by Sp, detection regime, sample size, number of genes, type of fitness
landscape, and CPM. In all models, the response variable was the average from the five split
replicates of each fitness landscape by sample size by detection regime combination, and fit-
ness landscape id (not type) was a random effect. When the dependent variable had values
exactly equal to 0 or 1, we used the transformation suggested in [49]. Models were fitted using
sum-to-zero contrasts [50] and all regressors were used as discrete regressors, except Sp, which
has been scaled (mean 0, variance 1) for easier interpretation; the coefficients of the main effect
terms of the discrete regressors are the deviations from the average (see further details in sec-
tion 6 in S4 Text). We have used the glmmTMB [51] and car [52] packages for R [53] for statis-
tical model fitting and analysis.
Characteristics of the simulated fitness landscapes and genotypes
All the fitness landscapes used are shown in S1 Fig. We provide here a brief description of the
main features of the three different fitness landscapes and the simulated data sets. The three
types of fitness landscapes had comparable numbers of accessible genotypes but differed in the
number of local fitness maxima and reciprocal sign epistasis, as shown in Figures A to C in S2
Fig (representable fitness landscapes had a single fitness maximum with no reciprocal sign
epistasis, whereas RMF landscapes had the largest of both, and local maxima landscapes were
intermediate).
Simulations resulted in varied amounts of clonal interference, as measured by the average
frequency of the most common genotype (Figures D and E in S2 Fig); scenarios where clonal
sweeps dominated (i.e., those characterized by the smallest clonal interference) corresponded
to initial population sizes of 2000, with clonal interference being much larger at the other pop-
ulation sizes (Figure D in S2 Fig).
Simulations resulted in a wide range of numbers of paths to the maximum (number of dis-
tinct LODs: Figure F in S2 Fig). LOD diversities (Sp) ranged from 0.3 to 8.7 (Figure G in S2
Fig) with RMF models showing smaller Sp; RMF landscapes had the largest number and diver-
sity of observed local fitness maxima (Figures H and I in S2 Fig) and Sp was strongly associated
to the number of accessible genotypes (Figure J in S2 Fig). As designed, the number of muta-
tions of the fitness maxima were 7 and 10 in the representable landscapes; the mean number
of mutations were smaller in the fitness maxima of the local maxima and RMF landscapes
(Figure K in S2 Fig).
The number of different sampled genotypes was comparable between detection regimes
(Figure L in S2 Fig), but diversity differed (Figure M in S2 Fig), with the uniform detection
regime showing generally larger sampled diversity. The mean and median number of muta-
tions of sampled genotypes (Figures N and O in S2 Fig) differed between detection regimes,
being largest in the large detection regime, and smallest in the small detection regime; the
standard deviation and coefficient of variation in the number of mutations (Figures P and
Q in S2 Fig) were largest in the uniform detection regime (thus, the uniform detection
regime showed both the largest variation in number of mutations of genotypes and the larg-
est diversity of genotypes). Sample characteristics and the difference in sample characteristics
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between detection regimes were affected by type of fitness landscape (Figures M and P in
S2 Fig).
Cancer data sets
We have used twenty-two cancer data sets (including six different cancer types: breast, glio-
blastoma, lung, ovarian, colorectal, and pancreatic cancer). All of these data sets, except for the
breast cancer data sets BRCA_ba_s and BRCA_he_s (from [54]), have been used previously as
input for some CPM algorithms in [10, 14–16, 19, 34, 35], with the original sources of the data
being [55–65]. Details on sources, names, and how the data were obtained and processed are
provided in S5 Text.
These data sets vary in sample size (27 to 594 samples), number of features (from 7 to over
100), data types (nonsynonymous somatic mutations and copy number aberrations or both),
levels of analysis (genes, modules and pathways, exclusivity groups), patterns of number of
mutations per subject and frequency of mutations analyzed, and procedures for driver selec-
tion, and restriction of patient subtypes. The data sets, therefore, are a large representative
ensemble of data sets to which researchers have previously applied or might apply CPMs.
We have run the CPM analyses three times per data set, limiting the number of features
analyzed to the 7, 10, and 12 most common ones, so as to examine how our assessments
depend on the number of features analyzed; the first two thresholds use the same number of
features as the simulations. (For data sets with 7 or fewer features, there are no differences in
the data sets used under the 7, 10, and 12 thresholds; likewise for data sets with 8 to 10 features
with respect to thresholds 10 and 12).
We do not know the true paths of tumor progression, but we can use the bootstrap to assess
the robustness or reliability of the inferences. To do so, we repeated the process above with 100
bootstrap samples (section 1.2 in S5 Text). We computed JSo,b, the average JS between the dis-
tribution of paths to the maximum from the original data set and each of the bootstrapped
samples. Large differences in the distribution of paths between the analyses with the bootstrap
samples and the analysis with the original sample (i.e., large JSo,b) would suggest that the infer-
ences are unreliable and cannot be trusted (but small differences do not indicate that the
inferred paths match the distribution of the true ones).
Results
Predicting paths of evolution with CPMs
The CPMs used (four, two with two variants, yielding a total of six different procedures for
obtaining CPMs: H-CBN, MCCBN, OT, CAPRI_AIC, CAPRI_BIC, and CAPRESE) can be
divided into three groups: models that return trees (OT and CAPRESE) and two families
of models that return DAGs, CBN (H-CBN and MCCBN) and CAPRI (CAPRI_AIC and
CAPRI_BIC). Comparing within groups with respect to JS one member of the pair consis-
tently outperformed the other (see Figure A in S6 Text). OT (using probability-weighted
paths, see below) was significantly better than CAPRESE (paired t-test over all non-missing
56595 pairs of results: t56594 = −161.1, P< 0.0001), H-CBN was significantly better than
MCCBN (t56593 = −42.6, P< 0.0001), and CAPRI_AIC was significantly better than CAPRI_
BIC (t56594 = −41.9, P< 0.0001). In what follows, therefore, and for the sake of brevity, we will
focus on OT, H-CBN, and CAPRI_AIC, since the overall performance of their alternatives is
worse.
Fig 3 shows how the performance measures for OT, H-CBN, and CAPRI_AIC change
with sample size for all combinations of type of landscape, detection regime, and number of
genes (see Figure B in S6 Text for the probability of recovering the most common LOD). The
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Fig 3. Summary performance measures (see definitions in Measures of performance and predictability) for OT,
CAPRI_AIC, and H-CBN for all combinations of sample size, type of landscape, detection regime, and number of
genes. (A) Jensen-Shannon divergence (JS); (B) 1—recall; (C) 1—precision. For all measures, smaller is better. For OT
and H-CBN, JS (panel A) and 1-precision (panel C) use probability-weighted paths (see text). Each point represented is
the average of 210 points (35 replicates of each one of the six combinations of 3 initial size by 2 mutation rate regimes
—see Overview of the simulation study); we are thus marginalizing over mutation rate by initial simulation size
combinations. Each one of the 210 points is, itself, the average of five runs on different partitions of the simulated data.
See Figure A in S6 Text for results for all six procedures used (four, two with two variants: H-CBN, MCCBN, OT,
CAPRI_AIC, CAPRI_BIC, and CAPRESE).
https://doi.org/10.1371/journal.pcbi.1007246.g003
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measures of JS and 1-precision for OT and H-CBN (and MCCBN) use probability-weighted
paths computed as explained in Measures of performance and predictability, because there
was strong evidence for all three models that the probability-weighted paths led to better
results (JS, paired t-test over all pairs: OT, t56594 = −195.8, P< 0.0001; H-CBN: t56594 = −222.3,
P< 0.0001; MCCBN: t56593 = −149.0, P< 0.0001; 1-precision: OT: t56594 = −187.6, P< 0.0001;
H-CBN: t56594 = −217.6, P< 0.0001; MCCBN: t56593 = −130.3, P< 0.0001). (See also Figures D
to F in S6 Text). Overall, H-CBN was the model with the best performance (P< 0.0001 from
all pairwise comparisons between the six procedures with Tukey’s contrasts and single-step
multiple testing p-value adjustment [66] on linear mixed-effects models with landscape by
split replicate as random effect). It must be noted, however, that all CPMs can show large vari-
ability in performance (Figure G in S6 Text).
JS differed between type of landscape, number of genes, detection regime, and sample size,
but the magnitude and even direction of effects differed between combinations of those fac-
tors, as seen in Figs 3 and 4. Generalized linear mixed-effects models fitted to the complete
data set and to the different combinations of CPM and type of landscape (see section 11 in S6
Text) also showed highly significant (P< 0.0001) two-, three-, and four-way interactions
between most of the factors, in particular those involving type of landscape and detection
regime. Type of landscape and detection regime also had very strong effects in the variability
of the estimates, with relative variabilities that could reach 20% with small sample sizes
(Figure G in S6 Text).
Under representable fitness landscapes, performance improved with increasing sample size
and with the uniform detection regime. Performance was worse in fitness landscapes of 10
genes (Figs 3A and 4 top row); the decrease in performance with increasing number of genes
is related to CPMs both missing evolutionary paths (Fig 3B), and allowing paths that are not
used by evolution (Fig 3C). With CAPRI_AIC the effect of sample size was much weaker and
increases in sample size could lead to decreases in performance, specially under the uniform
detection regime (highly significant, P< 0.0001, interactions of detection and sample size —
section 11 in S6 Text). This is attributable to CAPRI_AIC excluding many paths taken during
evolution (Fig 3B). This behavior was caused by CAPRI_AIC sometimes allowing only a few
or even just one path to the maximum (Figure H in S6 Text); see also next section.
Under the RMF landscape overall performance was worse. Increasing sample size for OT
and H-CBN led to minor decreases in performance (Figs 3 and 4 bottom row). CPMs failed to
capture about 50% of the evolutionary paths (or fractions of paths) to the local maxima (Fig
3B) and included more than 75% of paths (or fractions of paths) that were never taken by evo-
lution (Fig 3C). The behavior under local maxima was similar to that of representable fitness
landscapes in terms of the direction of most effects, but effects were generally weaker, with the
exception of evolutionary unpredictability.
Evolutionary unpredictability itself had a strong effect on performance. There were highly
significant interactions (P< 0.0001) between evolutionary unpredictability (as measured with
Sp), detection regime, and sample size, within representable and local maxima landscapes, as
well as in the overall models (section 11 in S6 Text). In most scenarios, performance was worse
with larger unpredictability (larger Sp) as seen by the positive slopes of JS on Sp (Fig 5). But
under representable landscapes, in the large detection regime and for sample sizes 50 and 200,
larger evolutionary unpredictability was associated with better performance. Under RMF fit-
ness landscapes, large evolutionary unpredictability was associated with poorer performance
over all sample sizes. Under local maxima, the effect of evolutionary unpredictability depended
strongly on sample size and detection regime, with reversal of effects from sample size of 50
compared to 4000 under the large detection regime, similar to the ones in representable
landscapes.
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Inferring evolutionary unpredictability from CPMs
Fig 6A shows the ratio of inferred to true evolutionary unpredictability, Sc/Sp. Under repre-
sentable fitness landscapes, for H-CBN this ratio remained close to 1 over all combinations of
detection regime, number of genes, and sample size; the values were closest to one with sample
size 4000 and under the uniform detection regime. This is in spite of large differences in the
ratio of estimated number of paths to the maximum over true number of paths to the maxi-
mum (Fig 6B). This good performance is a consequence of both using probability-weighted
paths by H-CBN (and OT) and of changes in scale (diversities use logarithms). Patterns for
CAPRI_AIC seemed dominated by the tendency of CAPRI_AIC to only allow very few paths
as the sample size grows large (see also Figure H in S6 Text) and were also the consequence of
CAPRI_AIC’s inability to produce probability-weighted paths. For all CPMs type of landscape
Fig 4. Coefficients from generalized linear mixed-effects models, for JS as dependent variable, with separate models fitted to each combination of
CPM and type of fitness landscape. Coefficients are from models with sum-to-zero contrasts (see text and Section 6 in S4 Text). Within each panel,
coefficients have been ordered from left to right according to decreasing absolute value of coefficient. The dotted horizontal gray line indicates 0 (i.e. no
effect). Coefficients with a large positive value indicate factors that lead to a large decrease in performance (increase in JS). Only coefficients that
correspond to a term with a P-value<0.05 in Type II Wald chi-square tests are shown. The coefficient that corresponds to Number of genes 7 is not
shown (as it is minus the coefficient for 10 genes —from using sum-to-zero contrasts). “N_Genes”: number of genes; “S_Size”: sample size; “Detect”:
detection regime; “Sp”: LOD diversity (Sp).
https://doi.org/10.1371/journal.pcbi.1007246.g004
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affected the quality of estimates: under local maxima and specially RMF the number and diver-
sity of paths tended to be overestimated, sometimes by large factors. In summary, and regard-
less of fitness landscape, the estimates of evolutionary unpredictability from H-CBN (Sc) could
be used to obtain an upper bound of the true evolutionary unpredictability.
And how does the estimated evolutionary unpredictability change with the true evolution-
ary unpredictability? Fig 6C shows that the slopes of regressions of estimated unpredictability
from CPMs (Sc) on true unpredictability (Sp) changed depending on fitness landscape, detec-
tion regime, and sample size, including slopes over and under 1, and even inversion of signs.
Cancer data sets
We have used H-CBN (the best performing model in the simulations) on twenty-two cancer
data sets to examine the estimated evolutionary unpredictability and to assess the reliability of
the estimates. The results are shown in Fig 7 (see Figure A in S5 Text for ranges of bootstrap
runs). Unreliability (JSo,b —section Cancer data sets) was large for most data sets, and very
large for some of them. These results would be expected, even if the true fitness landscapes
were representable ones, as most of the data sets have small sample sizes (less than 1000),
and we have seen that performance is poor (large JS) for that range of sample sizes (Fig 3A).
For these data sets there was no relationship between JSo,b and sample size (Fig 7A), and
when the same data set was analyzed using pathways/modules and genes, performance was
generally better using pathways or modules (Pan_pa vs. Pan_ge, Col_pa vs. Col_g, GBM_pa
vs. GBM_ge, GBM_mo vs. GBM_CNA). Within data sets, and for all data sets, as the number
of features analyzed increased performance either decreased or stayed the same (i.e., for data
sets with more than 7 features, unreliability at the 10 feature threshold, JS10o;b, was larger or
Fig 5. Estimated slopes of the regression of Jensen-Shannon divergence (JS) on LOD diversity (Sp) for all combinations of sample size by type of
landscape by detection regime by number of genes. A beta regression was fitted to each subset of data. Each regression was fitted to 210 points, each of
which is itself the average of five replicates, one for each of the five runs on different partitions of the simulated data.
https://doi.org/10.1371/journal.pcbi.1007246.g005
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Fig 6. Path diversities and number of paths inferred from CPMs relative to the values from LODs. (A) Average of
the ratio of diversity of paths to the maximum inferred by the CPMs (Sc) relative to the true LOD diversity (Sp), for all
combinations of type of landscape by detection regime by number of genes by sample size. (B) Like (A), but for
number of paths to the maximum from the CPMs relative to the observed number of distinct LODs. As in Fig 3, each
point is the average of 210 points. (C) Slope of the regression of Sc on Sp; each point is thus a slope from a regression of
210 points, each of which is itself the average of 5 replicates (see Fig 5). (A) shows whether evolutionary
unpredictability (Sp) tends to be over- or under-estimated by Sc; (C) shows how Sc changes with Sp —see section 13 in
S6 Text for an example of positive ratios with negative slopes.
https://doi.org/10.1371/journal.pcbi.1007246.g006
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equal to unreliability at the 7 feature threshold, JS7o;b; for data sets with more than 10 features,
JS7o;b � JS
10
o;b � JS
12
o;b: Figure A in S5 Text).
There were mild trends for an association between smaller JSo,b and smaller numbers of fea-
tures and smaller Sc (Fig 7B and 7C), with notable exceptions: the Pancreas Pathways (Pan_pa)
data set had very small JSo,b even for moderate number of features, and the All Pathways
Fig 7. Summary patterns for JSo,b (average JS for the full data compared to the bootstrap runs) and unpredictability for the cancer data sets. (A)
JSo,b vs. sample size of data sets. (B) JSo,b vs. number of features analyzed for each data set. (C) JSo,b vs. estimated evolutionary unpredictability; in the
bottom x-axis, Sc is shown in terms of number of equiprobable paths; orange and salmon vertical lines indicate 20 and 100 equiprobable paths,
respectively. All results shown are from analysis with up to 12 features. Values shown for JSob are the average of the 100 bootstrap runs; values for
unpredictability (Sc or equiprobable paths) are from the analysis with the original, non-bootstrapped, data.
https://doi.org/10.1371/journal.pcbi.1007246.g007
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(all_pa) data set had a relatively small JSo,b even though it used 12 features and had a large Sc;
the GBM CNA modules (GBM_mo) data set also showed moderate JSo,b in spite of having
nine features and relatively large Sc. Conversely, some data sets with small Sc had extremely
unreliable path predictions (e.g., BRCA_ba_s, Col_mss_co, Col_msi_co, GBM_ge).
Values for Sc were well within the ranges of Sc estimated by H-CBN for the simulated data
(Figure K in S6 Text). As expected, Sc increased with the number of features analyzed (see also
Figure D in S5 Text). Given the results from section Inferring evolutionary unpredictability
from CPMs, where generally Sp< Sc, this suggests that the true evolutionary unpredictability
(when analyzing up to 12 features) for 13 of the data sets should be less than that correspond-
ing to about 100 equiprobable paths to the maximum, but only eight are below the much
more manageable, and useful, 20 equiprobable paths (Fig 7D). The Pan_pa, GBM_coo, and
BRCA_he_s show outstanding patterns in Fig 7. Examination of the output from H-CBN
revealed that there was one single path with estimated probability > 0.97 for Pan_pa, and two
paths to the maximum of about equal probability that together added> 0.95 for GBM_coo.
BRCA_he_s had only four features but mutations in SRPRA and PIK3R1 were present each in
only four individuals (different individuals for the two mutations); repeated runs of H-CBN
led to different sets of restrictions being inferred which, because there are few paths to the
maximum, and some had large probabilities (> 0.5), resulted in large differences in JS statistic
between runs.
Discussion
Can we predict the likely course of tumor progression using CPMs? We have examined the
performance of six different procedures for obtaining CPMs (four CPMs, two of them with
two variants: H-CBN and MCCBN, OT, CAPRI_AIC and CAPRI_BIC, and CAPRESE).
H-CBN was the best performing CPM in our study. Using H-CBN under the representable
fitness landscapes (the scenarios that agree with CPMs’ assumptions) returned estimates of
the probability of paths of tumor evolution that were not far from the true distribution of
paths of evolution (Fig 3A) when sample size was very large. But we find that, even under
representable fitness landscapes, performance with moderate (and more realistic) sample
sizes was considerably worse and was affected by detection regime. The analysis of the
twenty-two cancer data sets revealed that performance (as measured by JSo,b, an indicator of
unreliability of inferences) was poor or very poor for most data sets. Even data sets with few
features and small estimated diversity of paths to the maximum, Sc, showed very unreliable
predictions.
What factors, and how, affect performance? Under representable fitness landscapes, perfor-
mance on simulated data was affected by the number of features, the dimension of the fitness
landscape: JS was worse with 10 than with 7 genes (Figs 3 and 4). Increasing sample size
improved performance (Fig 3). Detection regime and evolutionary unpredictability, as mea-
sured by LOD diversity (Sp), affected individually and jointly all performance measures (Figs 3
and 5). Increased evolutionary unpredictability was detrimental to performance under most
conditions (Fig 5). Detection regime was a key determinant of performance, as already found
in previous work [31, 67]; performance was better under the uniform detection regime and,
more importantly, detection regime affected how the rest of the factors (evolutionary unpre-
dictability, sample size, and number of features) impacted on performance (Figs 3 to 5).
The analysis of the twenty-two cancer data sets also indicated number of features as a major
determinant of performance. Across data sets, unreliability of inferences (JSo,b) increased with
number of features (Fig 7). Within-data set unreliability also increased as the number of fea-
tures increased (Figure A in S5 Text; note that an increase in the number of features analyzed
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leads to an increase in the number of features with low frequency events). Interestingly, the
driver-selected data sets (Col_mss, Col_msi, BRCA_he_s, BRCA_ba_s) did not perform much
better than data sets with a simple frequency-based selection of features (e.g., Lu, Ov, or com-
parison Ov with Ov_drv). Even data sets with very careful, manually-curated selection of
drivers and “exclusivity groups” and where variability due to subtypes has been minimized
(Col_msi, Col_msi_co, Col_mss, Col_mss_co, ACML_co, BRCA_he_s and BRCA_ba_s)
showed very large JSo,b. And BRCA_he_s, with only four features, showed much larger JSo,b
than GBM_coo and Pan_pa (with 3 and 7 features, respectively), due to the presence of two
low frequency alterations.
These results bring forth the problem of the selection of the relevant features for analysis
[10, 15, 68] and whether sample size is large enough relative to the number and frequency of
features considered. We have previously shown that feature selection can have a very detri-
mental impact on the performance of CPMs [67]. Using pathways instead of genes in the anal-
yses (e.g., [68, 69]) can alleviate some of the problems of feature selection. Data sets coded as
pathways or modules generally reduced the presence of low-frequency alterations (Figures B
and C in S5 Text). Pathways can also improve predictability and how close the estimates of
path distributions are to the truth because they are more similar to heritable phenotypes,
which often have smoother phenotype-fitness maps and tend to show more repeatable evolu-
tion ([5]; see also [70], but also [71, 72]). Selection of the appropriate level of analysis is also a
relevant question given non-genetic heterogeneity and phenotypic variance, which can speed
up the evolutionary process and adaptation to novel selective pressures [73–75], including the
evolutionary processes of cancer [76]. One of the consequences of phenotypic variance is the
smoothing of the fitness landscape, leading to “lower peaks and shallower valleys” [77, p.
2311]. It is possible, thus, that in the presence of phenotypic variance, analysis closer to the
phenotype could better fulfil the assumptions of CPMs. Gerstung et al. [10] found that analysis
using pathways gave stronger evidence for order constraints than analysis using genes, and we
also see in Fig 7 that both Sc and JSo,b tend to decrease if we use pathways or modules (Pan_pa
vs. Pan_ge, Col_pa vs. Col_g, GBM_ge vs. GBM_pa, GBM_mo vs. GBM_CNA). Using so-
called “exclusivity groups” (sensu [15]) to identify “fitness equivalent alterations” is a similar,
though not identical, procedure that in this paper showed only modest improvements in JSo,b
(Col_mss_co vs. Col_mss, Col_msi_co vs. Col_msi, ACML_co vs. ACML). This can be due to
particularities of these data sets (e.g., large number of features relative to number of subjects)
or the intrinsic difficulties of identifying true fitness equivalent groups via “hard/soft exclusivi-
ties”. However, although analysis using pathways/modules/exclusivity groups might lead to
more reliable results from the predictability point of view, the identification of paths at the
gene level is still the ultimate goal for therapeutic interventions (see [78]). Regardless of the
details of the procedure for collapsing and reducing features, our results suggest that further
work on feature selection should consider reduction of variability of estimates of evolutionary
paths as a key component.
Hosseini et al. [36] reanalized the DAG-derived representable and a subset (those where the
fully mutated genotype has the largest fitness) of the DAG-derived non-representable fitness
landscapes in [31]. They find good agreement between the distributions of paths to the maxi-
mum from H-CBN and the fitness landscape-based probability distribution of paths to the
maximum computed assuming SSWM. Our results for H-CBN under the best conditions are
not as optimistic. Two differences in the studies explain the differences. First, [36] computes
the fitness landscape-based probability of paths assuming a SSWM regime and restricting the
analysis to fitness landscapes where the fully mutated genotype has the largest fitness, while
our analyses directly examine the distribution of the paths to the maximum in each simulation
(LODs), without restricting the evolutionary regime and the fitness landscapes; second, [36]
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uses H-CBN with the very large sample size of 20000 (the full data sets in [31]), while we use a
more realistic range of sample sizes.
Even very good performance, though, needs to be interpreted with care. Very good perfor-
mance simply tells us that the true and estimated probability distributions of the paths to the
maximum agree closely. If the true evolutionary unpredictability is large, then for practical
purposes our capacity to predict what will happen (in the sense of providing a small set of
likely outcomes) is very limited. Ranges of diversities of 3.2 to 6.0, equivalent to 25 to 400 equi-
probable paths, were common in the simulated data (Figure K in S6 Text) and are comparable
to the ranges in most cancer data sets with 7 and 10 feature thresholds (Figure A in S5 Text).
The inability to narrow down the likely paths to a small set of paths in these cases is not a limi-
tation of the CPMs, but a problem inherent to the unpredictability of the evolutionary process
in many scenarios, which could severely limit the usefulness of even perfect predictions.
The discussion above has centered on representable fitness landscapes. As argued before,
fitness landscapes with local fitness maxima are probably common in cancer. With local fitness
maxima, achieving good recall involves the relatively easier task of getting right the first part of
short paths to the maximum. But good recall was more than offset by low precision and overall
predictability was very poor. In fitness landscapes with local maxima, CPMs are fitting models
with paths of tumor progression that extend beyond the true end point of the progression. In
RMF fitness landscapes, in addition to local peaks, not even the set of accessible genotypes can
be represented by DAGs of restrictions (see [31], and Fig 1). The violations of assumptions in
RMF and local maxima fitness landscapes explain the decreases in the relevance of sampling
regime and why increasing sample size has negligible (or even detrimental) effects in these fit-
ness landscapes (Figs 3 and 4). Remarkably, regardless of type of fitness landscape (i.e., even
under violation of assumptions), and for the two tasks considered (prediction of paths and
estimating unpredictability) performance of CPMs that could return probability-weighted
paths (H-CBN, MCCBN, OT) was better when using probability-weighted paths; thus, further
improvement in these CPMs, even under violations of assumptions, might be possible by
recalibrating their output.
CPMs have been developed for cross-sectional data sets with a single observation per sub-
ject. If we instead had access to data sets comprised of many subjects sampled many times over
the course of tumor development we could directly compute the probabilities of the paths of
tumor progression without using CPMs (and, thus, without relying on CPMs’ assumptions
about fitness landscapes). Note, though, that using CPMs on multiple data points from one
single subject, such as from multi-region, single-cell data, would not provide estimates of prob-
abilities of paths of tumor progression since a single subject constitutes a single realization
of the evolutionary process. Caravagna et al. [79] have recently proposed a method that they
have used to infer repeated evolution across patients from data sets with moderate numbers of
multiple observations per patient. Further development, evaluation, and comparison of these
approaches with those using only cross-sectional data will become important as data sets with
moderate numbers of multiple data points per individual become more common.
Finally, returning to our second question, even if achieving good performance in predicting
the paths of tumor progression is unlikely, inferring evolutionary unpredictability could be an
easier task. Can we use inferences of evolutionary unpredictability from CPMs as estimates of
the true evolutionary unpredictability? Under representable fitness landscapes, H-CBN, the
best performing model also for this task (Fig 6B), returned values of Sc very similar to Sp, the
evolutionary unpredictability estimated from the diversity of paths, and this held over detec-
tion regimes and sample sizes. Hosseini et al. [36] also find that the estimates of predictability
from H-CBN correlate well with the fitness landscape-based evolutionary predictability (esti-
mated assuming SSWM in fitness landscapes where the fully mutated genotype has largest
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fitness), with slopes of the regression of CPM-based on landscape-based predictability gener-
ally slightly below 1, similar to our findings (Fig 6C). These good results do not hold under the
other two types of fitness landscapes that we analyzed: evolutionary unpredictability is overes-
timated and increasing sample size made the problems worse, and different evolutionary sce-
narios, sample sizes, and detection regimes have different relationships of estimated and true
unpredictability (Fig 6C). But our results indicate that we can use H-CBN to set upper bounds
on the true Sp; obtaining tighter estimates is an objective for further research to explore. And
here our analysis of twenty-two cancer data sets suggests that the true evolutionary unpredict-
ability of at least some cancer scenarios might be reasonably small, specially if Sc is overestimat-
ing the true unpredictability.
Conclusion
The answer to the question “can we predict the likely course of tumor progression using
CPMs?” is, unfortunately, at least for the models examined, “only with moderate success and
only under representable fitness landscapes and with very large sample sizes; but even perfect
predictions might be of little use if evolutionary unpredictability is large”. Estimating upper
bounds to evolutionary unpredictability is a more modest, though more likely to succeed, use
of CPMs. Promisingly, several cancer data sets showed low evolutionary unpredictability.
There are three key difficulties for successful prediction: the sheer size of the problem even for
moderate numbers of genes, the intrinsic evolutionary unpredictability in many scenarios, and
the deviations from the assumptions of CPMs that are likely to hold in most cancer data. Fur-
ther methodological work to allow CPMs to deal with rugged, multi-peaked, fitness landscapes
could improve their usefulness to predict tumor evolution. In addition to the caveat about
using these models under scenarios where performance is very poor, this paper raises the gen-
eral question of what can we really predict about likely paths of tumor progression from cross-
sectional data, for instance to guide therapeutic interventions. At a minimum, measures such
as JSo,b and Sc with CPMs that return probability-weighted paths should probably become rou-
tine as ways of providing a sense of the reliability of predictions and for assessing whether the
predictions could be of any practical use.
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